The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4146-4157

  Xi, Gang ^a   Solum, Melissa A ^a   Wai, Christine ^a   Maile, Laura A ^a   Rosen, Clifford J ^b   Clemmons, David R ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b Maine Medical Center Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; HEPARIN BINDING PROTEIN; LEPTIN; SOMATOMEDIN BINDING PROTEIN 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL DIFFERENTIATION; CONTROLLED STUDY; FAT MASS; IN VIVO STUDY; INTRAABDOMINAL FAT; LIPID STORAGE; MALE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROADIPOCYTE; PROTEIN BLOOD LEVEL; PROTEIN DOMAIN; WEIGHT GAIN;

ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; EPIDIDYMIS; HEPARIN; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUTATION; PROTEIN STRUCTURE, TERTIARY;

EID: 84886576300     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1236     Document Type: Article

References (53)

1. Chakrabarty S, Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther. 2006;5(2): 189-197.
2. BoneyCM,Moats-StaatsBM,Stiles AD, D'Ercole AJ. Expression of insulin-like growth factor-I (IGF-I) and IGF-binding proteins during adipogenesis. Endocrinology. 1994;135(5): 1863-1868.
3. Wheatcroft SB, Kearney MT. IGF-dependent and IGF-independent actions of IGF-binding protein-1 and -2: implications for metabolic homeostasis. Trends Endocrinol Metab. 2009;20(4): 153-162.
4. Nam SY, Lee EJ, Kim KR, et al. Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGFbinding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone. Int J Obes Relat Metab Disord. 1997;21(5): 355-359.
5. Martin RM, Holly JM, Davey Smith G, Gunnell D. Associations of adiposity from childhood into adulthood with insulin resistance and the insulin-like growth factor system: 65-year follow-up of the Boyd Orr Cohort. J Clin Endocrinol Metab. 2006;91(9): 3287-3295.
6. Hu D, Pawlikowska L, Kanaya A, et al. Serum insulin-like growth factor-1 binding proteins 1 and 2 and mortality in older adults: the Health, Aging, and Body Composition Study. J Am Geriatr Soc. 2009;57(7): 1213-1218.
7. Wheatcroft SB, Kearney MT, Shah AM, Ezzat VA, Miell JR, Modo M, Williams SC, Cawthorn WP, Medina-Gomez G, Vidal-Puig A, Sethi JK, Crossey PA. IGF-binding protein-2 protects against the development of obesity and insulin resistance. Diabetes. 2007;56(2): 285-294.
8. DeMambro VE, Clemmons DR, Horton LG, et al. Gender-specific changes in bone turnover and skeletal architecture in igfbp-2-null mice. Endocrinology. 2008;149(5): 2051-2061.
9. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocr Rev. 2002;23(6): 824-854.
10. Clemmons DR. Use of mutagenesis to probe IGF-binding protein structure/function relationships. Endocr Rev. 2001;22(6): 800-817.
11. Shimasaki S, Ling N. Identification and molecular characterization of insulin-like growth factor binding proteins (IGFBP-1, -2, -3, -4, -5 and -6). Prog Growth Factor Res. 1991;3(4): 243-266.
12. Mohan S, Baylink DJ. IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol. 2002;175(1): 19-31.
13. Kuang Z, Yao S, Keizer DW, et al. Structure, dynamics and heparin binding of the C-terminal domain of insulin-like growth factorbinding protein-2 (IGFBP-2). J Mol Biol. 2006;364(4): 690-704.
14. Jones JI, Gockerman A, Busby WH Jr, Wright G, Clemmons DR. Insulin-like growth factor binding protein 1 stimulates cell migration and binds to the α 5 β 1 integrin by means of its Arg-Gly-Asp sequence. Proc Natl Acad Sci USA. 1993;90(22): 10553-10557.
15. Schütt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW.Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol. 2004;32(3): 859-868.
16. Kawai M, Breggia AC, DeMambro VE, et al. The heparin-binding domain of IGFBP-2 has insulin-like growth factor binding-independent biologic activity in the growing skeleton. J Biol Chem. 2011; 286(16): 14670-14680.
17. DeMambro VE, Maile L, Wai C, et al. Insulin-like growth factorbinding protein-2 is required for osteoclast differentiation. J Bone Miner Res. 2012;27(2): 390-400.
18. Gockerman A, Prevette T, Jones JI, Clemmons DR. Insulin-like growth factor (IGF)-binding proteins inhibit the smooth muscle cell migration responses to IGF-I and IGF-II. Endocrinology. 1995; 136(10): 4168-4173.
19. Shen X, Xi G, Maile LA, Wai C, Rosen CJ, Clemmons DR. Insulinlike growth factor (IGF) binding protein 2 functions coordinately with receptor protein tyrosine phosphataseβ and the IGF-I receptor to regulate IGF-I-stimulated signaling. Mol Cell Biol. 2012;32(20): 4116-4130.
20. Imai Y, Moralez A, Andag U, Clarke JB, Busby WH Jr, Clemmons DR. Substitutions for hydrophobic amino acids in the N-terminal domains of IGFBP-3 and -5 markedly reduce IGF-I binding and alter their biologic actions. J Biol Chem. 2000;275(24): 18188-18194.
21. Xi G, Shen X, Clemmons DR. p66shc negatively regulates insulinlike growth factor I signal transduction via inhibition of p52shc binding to Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 leading to impaired growth factor receptorbound protein-2 membrane recruitment. Mol Endocrinol. 2008; 22(9): 2162-2175.
22. Danno H, Jincho Y, Budiyanto S, Furukawa Y, Kimura S. A simple enzymatic quantitative analysis of triglycerides in tissues. J Nutr Sci Vitaminol (Tokyo). 1992;38(5): 517-521.
23. Kelly SA, Nehrenberg DL, Hua K, Garland T Jr, Pomp D. Exercise, weight loss, and changes in body composition in mice: phenotypic relationships and genetic architecture. Physiol Genomics. 2011; 43(4): 199-212.
24. DeMambroVRC, Clemmons D. IGFBP-2 null mice develop obesity and insulin resistance with aging. Growth Horm IGF Res. 2008; 18(suppl 1):S26.
25. Hedbacker K, Birsoy K, Wysocki RW, et al. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell Metab. 2010;11(1): 11-22.
26. Rehfeldt C, Renne U, Sawitzky M, Binder G, Hoeflich A. Increased fat mass, decreased myofiber size, and a shift to glycolytic muscle metabolism in adolescent male transgenic mice overexpressing IGFBP-2. Am J Physiol Endocrinol Metab. 2010;299(2):E287-E298.
27. Chan SS, Schedlich LJ, Twigg SM, Baxter RC. Inhibition of adipocyte differentiation by insulin-like growth factor-binding protein-3. Am J Physiol Endocrinol Metab. 2009;296(4):E654-E663.
28. Peter MA, Winterhalter KH, Böni-Schnetzler M, Froesch ER, Zapf J. Regulation of insulin-like growth factor-I (IGF-I) and IGF-binding proteins by growth hormone in rat white adipose tissue. Endocrinology. 1993;133(6): 2624-2631.
29. Li Z, Picard F. Modulation of IGFBP2 mRNA expression in white adipose tissue upon aging and obesity. Horm Metab Res. 2010; 42(11): 787-791.
30. Kuang Z, Yao S, McNeil KA, et al. Cooperativity of the N- and C-terminal domains of insulin-like growth factor (IGF) binding protein 2 in IGF binding. Biochemistry. 2007;46(48): 13720-13732.
31. Parker A, Clarke JB, BusbyWHJr, Clemmons DR. Identification of the extracellular matrix binding sites for insulin-like growth factorbinding protein 5. J Biol Chem. 1996;271(23): 13523-13529.
32. Firth SM, Clemmons DR, Baxter RC. Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding. Endocrinology. 2001;142(5):2147.
33. Domené HM, Hwa V, Jasper HG, Rosenfeld RG. Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab. 2011; 25(1): 101-113.
34. Russo VC, Schütt BS, Andaloro E, et al. Insulin-like growth factor binding protein-2 binding to extracellular matrix plays a critical role in neuroblastoma cell proliferation, migration, and invasion. Endocrinology. 2005;146(10): 4445-4455.
35. Levi J, Huynh FK, Denroche HC, et al. Hepatic leptin signalling and subdiaphragmatic vagal efferents are not required for leptin-induced increases of plasma IGF binding protein-2 (IGFBP-2) in ob/ob mice. Diabetologia. 2012;55(3): 752-762.
36. Ooi GT, Tseng LY, Rechler MM. Transcriptional regulation of the rat IGFBP-1 and IGFBP-2 genes. Growth Regul. 1993;3(1):14-17.
37. Radetti G, Bozzola M, Pasquino B, et al. Growth hormone bioactivity, insulin-like growth factors (IGFs), and IGF binding proteins in obese children. Metabolism. 1998;47(12): 1490-1493.
38. Ballerini MG, Ropelato MG, Domené HM, Pennisi P, Heinrich JJ, Jasper HG. Differential impact of simple childhood obesity on the components of the growth hormone-insulin-like growth factor (IGF)-IGF binding proteins axis. J Pediatr Endocrinol Metab. 2004; 17(5): 749-757.
39. Argente J, Caballo N, Barrios V, et al. Multiple endocrine abnor-malities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recuperation. J Clin Endocrinol Metab. 1997;82(7): 2084-2092.
40. Rasmussen MH, Juul A, Hilsted J. Effect of weight loss on free insulin-like growth factor-I in obese women with hyposomatotropism. Obesity (Silver Spring). 2007;15(4): 879-886.
41. Voskuil DW, Bueno de Mesquita HB, et al. Determinants of circulating insulin-like growth factor (IGF)-I and IGF binding proteins 1-3 in premenopausal women: physical activity and anthropometry (Netherlands). Cancer Causes Control. 2001;12(10): 951-958.
42. Ahmed RL, Thomas W, Schmitz KH. Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev. 2007;16(3): 593-597.
43. Li Z, Martin J, Poirier P, et al. Upregulation of plasma insulin-like growth factor binding protein 2 levels after biliopancreatic diversion in humans. Obesity (Silver Spring). 2012;20(7): 1469-1473.
44. Heald AH, Kaushal K, Siddals KW, Rudenski AS, Anderson SG, Gibson JM. Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker for the metabolic syndrome. Exp Clin Endocrinol Diabetes. 2006;114(7): 371-376.
45. Arafat AM, Weickert MO, Frystyk J, et al. The role of insulin-like growth factor (IGF) binding protein-2 in the insulin-mediated decrease in IGF-I bioactivity. J Clin Endocrinol Metab. 2009;94(12): 5093-5101.
46. Attia N, Tamborlane WV, Heptulla R, et al. The metabolic syndrome and insulin-like growth factor I regulation in adolescent obesity. J Clin Endocrinol Metab. 1998;83(5): 1467-1471.
47. Ko JM, Park HK, Yang S, Hwang IT. Influence of catch-up growth on IGFBP-2 levels and association between IGFBP-2 and cardiovascular risk factors in Korean children born SGA. Endocr J. 2012; 59(8): 725-733.
48. de KortSW,van Doorn J, van de SandeAG,LeunissenRW,Hokken-KoelegaAC.Serum insulin-like growth factor-binding protein-2 levels and metabolic and cardiovascular risk factors in young adults and children born small for gestational age. J Clin Endocrinol Metab. 2010;95(2): 864-871.
49. Rowlands MA, Holly JM, Gunnell D, et al. The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (prostate testing for cancer and treatment) study. Cancer Causes Control. 2010;21(11): 1829-1842.
50. Claudio M, Benjamim F, Riccardo B, Massimiliano C, Francesco B, Luciano C. Adipocytes IGFBP-2 expression in prepubertal obese children. Obesity (Silver Spring). 2010;18(10): 2055-2057.
51. Touskova V, Trachta P, Kavalkova P, et al. Serum concentrations and tissue expression of components of insulin-like growth factoraxis in females with type 2 diabetes mellitus and obesity: the influence of very-low-calorie diet. Mol Cell Endocrinol. 2012;361(1-2): 172-178.
52. Liu J, DeYoung SM, Zhang M, Zhang M, Cheng A, Saltiel AR. Changes in integrin expression during adipocyte differentiation. Cell Metab. 2005;2(3): 165-177.
53. Lin YT, Tang CH, Chuang WJ, Wang SM, Huang TF, Fu WM. Inhibition of adipogenesis by RGD-dependent disintegrin. Biochem Pharmacol. 2005;70(10): 1469-1478.